We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Exelixis Inc | NASDAQ:EXEL | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.015 | 0.07% | 21.915 | 21.91 | 21.92 | 22.30 | 21.86 | 22.00 | 392,329 | 16:16:10 |
From May 2019 to May 2024
By Matt Grossman
Bristol Myers Squibb Co. and Exelixis Inc. will get a priority review on applications with the Food and Drug Administration for combining Bristol's Opdivo and Exelixis's Cabometyx drugs to treat kidney cancer, the companies said Monday.
In a recent Phase 3 trial, the combination showed significant improvements in treating advanced renal-cell carcinoma compared with sunitinib, another drug. The trial, which included 651 patients, showed that the Opdivo-Cabometyx combination was associated with better health-related quality of life at most intervals, Bristol and Exelixis said.
The FDA has given the companies' applications for the combination treatment a target action date of Feb. 20.
In the U.S., Opdivo and Cabometyx have been approved on their own to treat cancers.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
October 19, 2020 07:33 ET (11:33 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Exelixis Chart |
1 Month Exelixis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
